Skip to content
‹ Back to IndustriesHealthcare

Semi-Living Cyborg Cells Generate Hope Within the Scientific Medical Community

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide and grow.

“The cyborg cells are programmable, do not divide, and preserve essential cellular activities and gain non-native abilities,” said biomedical engineer Cheemeng Tan from the University of California, Davis.

Biomedical advancements, such as the use of AI and cell therapy, bring with them the potential for myriad applications. One such promising application is the use of cyborg cells in oncology. Lab testing on tissue samples is underway, and the hope is cyborg cells could one day be used to deliver drugs to specific parts of the body.

Where might this technology take science in the coming years? Stephane Budel, Ph.D., a Founding Partner at DeciBio, and Andrew Aijian, Ph.D., a Partner at DeciBio, a strategy and market intelligence company for the precision medicine industry, provided some clues.

Stephane and Andrew’s Thoughts

“This is a very exciting paper. The advance of cyborg cells can have several therapeutic applications. A clear one is in oncology. There has been a lot of exciting development recently with CAR Ts. And people are discussing is it going to be autologous cells that come from the patient or allogeneic cells that would be easier to work with, where you would have like a massive batch of cells that you can use.

And there is now a third type of cells you could use: cyber cells. And in this case, you add synthetic polymers. The cells retain a number of functions, but they stop dividing. You can imagine people starting to be looking at a variety of different types of polymers and a variety of different types of synthetic pathways that they do to address cancer cells and beyond.” – Budel

“Yeah, this is the first I’ve been exposed to cyborg cells. The first I’m hearing of it. And I think what will be interesting is to see how this approach gets applied to different cell types; bacterial cells, human cells, cells with different functionalities, et cetera. And you can sort of really start to explore a vast space of possibilities and how you can use these types of cells for health applications, synthetic biology, industrial applications, especially if you can introduce non-native capabilities. In the paper, they cited the ability of these cells to be more resistant to peroxide environments, which has implications in industrial applications.

There’s sort of a huge space of functionalities and capabilities that you can explore. And I’m sure that researchers will be spending a lot of time optimizing the cells and the conditions to create many novel functionalities.” – Aijian

“Something we discussed as well is the need for these cells to actually evade the immune system. And there is certainly something that you can engineer in these cells as well that will be important if you want to inject them back into humans to treat virus conditions.” – Budel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512